Sanofi Cenrifki has received European Commission approval for the treatment of secondary progressive multiple sclerosis without relapses in the last two years, giving the company a major regulatory milestone in neurology and offering a new option for a difficult-to-treat stage of multiple sclerosis. The approval positions Cenrifki, also known as tolebrutinib, as the first disability-targeting medicine approved in the European Union for adults with this specific form of secondary progressive MS.
According to Sanofi’s press release published through TradingView, the European Commission approved Cenrifki after a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use. The decision was based on the HERCULES phase 3 study in non-relapsing SPMS, with supporting data from the GEMINI 1 and GEMINI 2 phase 3 studies in relapsing multiple sclerosis.
For Sanofi, the approval strengthens its position in neurology and immunoscience at a time when major pharmaceutical companies are seeking growth beyond traditional blockbuster categories. For patients, the decision is more significant because SPMS without relapses has long represented an area with high unmet need, where disability can continue to accumulate even when obvious relapse activity is absent.
Why the Sanofi Cenrifki Approval Matters
The Sanofi Cenrifki approval matters because it targets a form of multiple sclerosis where treatment options have been limited. Secondary progressive multiple sclerosis is a stage of MS marked by gradual disability accumulation. Patients may experience worsening fatigue, cognitive impairment, mobility problems, and loss of independence, often without clear relapse episodes.
That distinction is important. Many MS therapies have historically focused on relapse reduction or inflammatory flare control. But in non-relapsing SPMS, the central challenge is not frequent relapses. It is the slow accumulation of disability over time. That makes the approval of a disability-targeting medicine especially relevant.
Sanofi said Cenrifki is designed to target smoldering neuroinflammation, a key driver of disability progression in MS. This gives the product a differentiated position because it is not being presented only as another relapse-focused therapy. Instead, it is positioned around the underlying biology of progressive MS and disability accumulation.
For investors, this creates a potentially important commercial opportunity. Neurology remains a complex but strategically valuable area for large pharmaceutical companies. A first-in-class or differentiated therapy in a high-unmet-need population can strengthen pipeline credibility and support long-term growth narratives.
HERCULES Phase 3 Study Supports Approval
The approval was based primarily on the HERCULES phase 3 study, which evaluated tolebrutinib in patients with non-relapsing SPMS. The study was double-blind and randomized, enrolling patients with a diagnosis of SPMS, an expanded disability status scale score between 3.0 and 6.5, no clinical relapses in the previous 24 months, and documented disability accumulation over the previous 12 months.
Participants were randomized in a 2:1 ratio to receive either an oral daily dose of tolebrutinib or matching placebo for up to around 48 months. The primary endpoint was six-month confirmed disability progression, measured by changes in EDSS score.
Sanofi said HERCULES demonstrated that Cenrifki significantly delayed the onset of disability progression in non-relapsing SPMS. That endpoint is central because the therapy’s value proposition depends on slowing disability accumulation rather than only reducing relapse frequency.
The long study duration also matters. Progressive neurological diseases often require sustained observation to determine whether a therapy meaningfully changes the course of disease. A six-month confirmed disability progression endpoint gives regulators and physicians a more structured way to evaluate whether worsening is being delayed.
Supporting Data From GEMINI 1 and GEMINI 2
Sanofi also cited supporting data from the GEMINI 1 and GEMINI 2 phase 3 studies in relapsing multiple sclerosis. These studies compared tolebrutinib with teriflunomide, an oral disease-modifying medicine, in patients with RMS.
Participants in GEMINI 1 and GEMINI 2 were randomized to receive either tolebrutinib with placebo or teriflunomide with placebo. The primary endpoint in both studies was annualized relapse rate for up to around 36 months, while secondary endpoints included confirmed disease worsening, MRI lesion measures, and safety and tolerability.
The GEMINI studies are not the main basis for the SPMS without relapses approval, but they strengthen the overall clinical package. For regulators, supporting data across related MS populations can help build a broader understanding of efficacy, safety, and biological activity.
For Sanofi, this broader clinical program supports the idea that Cenrifki is not a narrow one-study asset. It is part of a larger MS development strategy, with evidence across different patient populations and disease expressions.
Cenrifki’s Mechanism Targets Smoldering Neuroinflammation
Cenrifki is an oral, brain-penetrant Bruton’s tyrosine kinase inhibitor. Sanofi designed it to target smoldering neuroinflammation, which is described as a key driver of disability progression in multiple sclerosis.
This mechanism is central to the product’s positioning. In progressive MS, disability can worsen even when relapses are not occurring. That suggests underlying inflammatory and neurodegenerative processes may continue below the surface. A therapy that penetrates the brain and targets those processes could address a major gap in current treatment approaches.
The once-daily oral administration may also be commercially relevant. Patients and physicians often value convenient dosing, especially in chronic diseases requiring long-term management. However, convenience must be weighed against safety monitoring requirements, particularly liver-related risks.
For market observers, the mechanism gives Sanofi a differentiated neurology story. The company is not simply adding another MS brand; it is presenting Cenrifki as a therapy aimed at disability accumulation in a progressive disease setting.
For ongoing updates on healthcare, biotech, earnings, and market-moving company developments, readers can follow Finprozone latest market news as major pharmaceutical approvals continue shaping investor sentiment.
Safety Monitoring Is a Key Part of the Launch
The approval also comes with important safety considerations. Sanofi said the safety profile of Cenrifki has been consistent across the clinical program, with COVID-19 and upper respiratory tract infections among the most common adverse events. However, significant liver enzyme elevations were also observed.
Drug-induced liver injury is an identified safety risk of Cenrifki. Sanofi emphasized that strict adherence to liver monitoring requirements and prompt management of liver enzyme elevations are important to mitigate this risk.
This point will matter for commercial adoption. Physicians may welcome a new treatment option for non-relapsing SPMS, but they will also need confidence in risk management procedures. Patients will need clear guidance, monitoring, and support.
Sanofi plans to support the German launch with a required Risk Management Program and Patient Support Program. That suggests the company is taking a careful introduction approach rather than treating the approval as a simple commercial rollout.
For investors, safety monitoring can affect adoption speed. A strong unmet need can drive physician interest, but liver monitoring requirements may create operational friction. The launch strategy will need to balance access, education, and safety discipline.
Germany Will Be the First Commercial Focus
Sanofi said it will make Cenrifki commercially available in Germany this year, working closely with local medical teams, treating MS specialists, and patients. Germany is often an important early European market for new medicines because of its healthcare infrastructure, specialist networks, and commercial relevance.
The German launch will provide an early test of real-world demand. Physicians will need to evaluate which patients fit the approved indication, how to manage liver monitoring, and how Cenrifki compares with existing approaches to SPMS care.
The launch may also influence perception across other European markets. If Germany adoption is careful but positive, it could support broader confidence. If monitoring concerns slow uptake, investors may moderate near-term expectations.
Sanofi’s language indicates that the company understands the need for controlled introduction. In progressive neurological disease, trust between physicians, patients, and manufacturers is critical. A successful launch will depend not only on approval but also on execution.
Market Implications for Sanofi
For Sanofi, Cenrifki’s EU approval adds to the company’s neurology pipeline credibility. Sanofi describes itself as an R&D-driven, AI-powered biopharma company focused on immunoscience, vaccines, and innovative medicines. Cenrifki fits that strategy because it sits at the intersection of neurology and immunology.
The company’s broader neurology pipeline includes projects in phase 3 studies across several diseases, including MS, chronic inflammatory demyelinating polyneuropathy, Alzheimer’s disease, Parkinson’s disease, age-related macular degeneration, and other neurological conditions.
From an investor perspective, the key question is whether Cenrifki can become commercially meaningful. Approval is a major milestone, but future revenue will depend on label scope, market access, pricing, physician adoption, patient identification, competition, and safety management.
Sanofi shares were listed under SAN and SNY in the press release. The approval may support the company’s long-term pipeline narrative, although individual stock performance can still be affected by broader market conditions, valuation, earnings expectations, and investor risk appetite.
Why SPMS Is a High-Unmet-Need Market
Secondary progressive multiple sclerosis creates a significant burden for patients, caregivers, healthcare systems, and economies. Sanofi noted that patients can experience fatigue, cognitive impairment, mobility challenges, and loss of independence. The company also said that, across major European economies, the yearly cost of MS-related disability exceeds the average annual income per person.
The social burden extends beyond the patient. As disability progresses, many people may need to reduce working hours or leave the workforce. Sanofi also cited that up to 82% of those living with severe MS rely on informal caregiving, showing how disability progression affects families and support networks.
This context is important because medicines targeting disability progression can have value beyond clinical endpoints. If a therapy delays disability worsening, it may help preserve independence, work capacity, and caregiver stability. That potential broader impact is part of why progressive MS remains such an important treatment area.
Cenrifki’s approval does not eliminate the challenges of SPMS, but it gives physicians and patients a new option in a population where the need is substantial.
Competitive and Regulatory Considerations
The approval also highlights the importance of regulatory differentiation. Cenrifki is approved in the EU for adults with SPMS without relapses in the last two years. It is also approved in Australia for non-relapsing SPMS and to slow disability accumulation in the absence of relapse activity with SPMS, and in the United Arab Emirates for SPMS without relapses in the last two years.
These approvals suggest that regulators in multiple regions have recognized the product’s potential role in non-relapsing SPMS. However, each market will have its own reimbursement, access, and physician adoption dynamics.
Competition in MS remains active. Treatments that reduce relapses, slow progression, or target different mechanisms are part of a complex landscape. Cenrifki’s positioning around disability accumulation gives it a differentiated angle, but commercial success will depend on how strongly that differentiation is perceived by neurologists and payers.
Investors should also monitor post-marketing safety data. For a medicine with identified drug-induced liver injury risk, real-world monitoring will be important to long-term confidence.
What Investors Should Watch Next
The first signal is the German launch. Commercial availability in Germany this year will provide an early view of physician and patient adoption.
The second signal is safety execution. Liver monitoring compliance and management of liver enzyme elevations will be crucial to physician confidence.
The third signal is reimbursement and access across Europe. Approval is only one step; broad use depends on market access decisions.
The fourth signal is Sanofi’s broader neurology pipeline. Cenrifki’s approval may increase investor attention on the company’s phase 3 neurology programs.
The fifth signal is real-world data. Evidence showing sustained disability benefit and manageable safety in clinical practice could strengthen long-term adoption.
FAQ
What is Sanofi Cenrifki approved for in the EU?
Sanofi Cenrifki, also known as tolebrutinib, is approved in the European Union for adults with secondary progressive multiple sclerosis without relapses in the last two years. The approval is based mainly on the HERCULES phase 3 study in non-relapsing SPMS.
Why is the Cenrifki approval important?
The approval is important because Cenrifki is positioned as the first disability-targeting medicine approved in the EU for SPMS without relapses. It targets disability progression, which remains one of the biggest unmet needs for patients with progressive multiple sclerosis.
What are the main safety concerns with Cenrifki?
Sanofi said the safety profile was consistent across the clinical program, with COVID-19 and upper respiratory tract infections among the most common adverse events. Significant liver enzyme elevations were observed, and drug-induced liver injury is an identified safety risk requiring strict liver monitoring.
What should investors watch after the approval?
Investors should watch the German launch, physician adoption, safety monitoring, reimbursement decisions, and Sanofi’s broader neurology pipeline. Commercial success will depend on real-world uptake, market access, and confidence in managing liver-related risks.
